Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

BACKGROUND & AIMS: Gut-homing lymphocytes that express the integrin α4β7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin α4β7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Gastroenterol Hepatol
Главные авторы: Lynch, Kate D., Chapman, Roger W., Keshav, Satish, Montano-Loza, Aldo J., Mason, Andrew L., Kremer, Andreas E., Vetter, Marcel, de Krijger, Manon, Ponsioen, Cyriel Y., Trivedi, Palak, Hirschfield, Gideon, Schramm, Christoph, Liu, Chung Heng, Bowlus, Christopher L., Estes, Derek J., Pratt, Daniel, Hedin, Charlotte, Bergquist, Annika, de Vries, Annemarie C., van der Woude, C. Janneke, Yu, Lei, Assis, David N., Boyer, James, Ytting, Henriette, Hallibasic, Emina, Trauner, Michael, Marschall, Hanns-Ulrich, Daretti, Luigi M., Marzioni, Marco, Yimam, Kidist K., Perin, Nicola, Floreani, Annarosa, Beretta-Piccoli, Benedetta Terziroli, Rogers, Jennifer K., Levy, Cynthia
Формат: Artigo
Язык:Inglês
Опубликовано: W.B. Saunders for the American Gastroenterological Association 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941216/
https://ncbi.nlm.nih.gov/pubmed/31100458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2019.05.013
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы